Overview

Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating patients with acute promyelocytic leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
6-Mercaptopurine
Arsenic Trioxide
Cytarabine
Daunorubicin
Mercaptopurine
Methotrexate
Tretinoin
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of acute promyelocytic leukemia (APL) by morphologic and flow cytometric
documentation (high orthogonal light scatter, lack of HLA-DR expression)

- Patients with classical APL as well as the microgranular variant (M3V) are
eligible

- In cases where the diagnosis is unclear, consultation with a
hematopathologist is required before enrolling the patient in the study

- Patients found to have cytogenetic abnormalities that do not produce the PML-RARĪ± gene
rearrangement will be removed from study and will not be included in data analysis

PATIENT CHARACTERISTICS:

- Patients will not be excluded because of performance status or comorbid disease

- Premenopausal female patients must have a negative pregnancy test

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy for APL except hydroxyurea